Introduction Metabolically–dysfunction–associated steatotic liver disease (MASLD) is a complex and heterogeneous condition where fibrosis plays a central role in disease progression and hepatocellular carcinoma (HCC) risk. Traditional histological fibrosis staging, although widely used, often fails to capture the nuanced microstructural and molecular heterogeneity of liver tissue.
Introduction
Metabolically–dysfunction–associated steatotic liver disease (MASLD) is a complex and heterogeneous condition where fibrosis plays a central role in disease progression and hepatocellular carcinoma (HCC) risk. Traditional histological fibrosis staging, although widely used, often fails to capture the nuanced microstructural and molecular heterogeneity of liver tissue. With advances in artificial intelligence and multi-omics, there is an opportunity to redefine fibrosis beyond conventional staging and link structural changes with biological pathways.
Problem Statement
Current fibrosis assessment lacks precision in predicting disease progression, molecular alterations, and HCC risk in MASLD. There is a critical need for advanced phenotyping tools that can integrate tissue architecture with molecular signatures to improve risk stratification and therapeutic targeting.
Summary
This study introduces an AI-based platform (FibroNest) that identifies detailed hepatic fiber morphologies and classifies them into distinct phenotypic components (FibroPCs). These AI-derived patterns were superior to conventional fibrosis staging in capturing key molecular pathways, including IL-6 signaling and therapeutic responsiveness (e.g., resmetirom). Notably, a specific phenotype (FibroPC4) was strongly associated with future HCC risk and revealed a unique microenvironment driven by interactions between hepatic stellate cells and periportal endothelial cells. This work establishes AI-driven fibrosis phenotyping as a powerful tool for precision hepatology, enabling better prediction of disease progression and targeted therapy in MASLD.
Introduction: Chronic hepatitis B (CHB), hepatic steatosis, and type 2 diabetes mellitus (T2DM) frequently coexist, creating a growing clinical challenge. This multinational study evaluated whether T2DM independently influences liver histology in treatment-naïve CHB patients with...
Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) remains a leading cause of cirrhosis, liver failure, and hepatocellular carcinoma, with limited treatment options. This study evaluated DT-109, a novel glycine-based tripeptide, as a gut-targeted therapy aimed at restoring...
Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) remains a leading cause of cirrhosis, liver failure, and hepatocellular carcinoma, with limited treatment options. This study evaluated DT-109, a novel glycine-based tripeptide, as a gut-targeted therapy aimed at restoring...
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to obesity, diabetes, and cardiovascular disease. While both tirzepatide and SGLT2 inhibitors improve metabolic health, comparative real-world data on long-term liver and cardiovascular outcomes have...
Introduction: GLP-1 receptor agonists (GLP-1RAs) have revolutionized obesity treatment, producing substantial weight loss and cardiometabolic benefits. However, many patients discontinue therapy because of cost, adverse effects, or limited access, and weight regain frequently follows. This...
Introduction: The treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) is evolving rapidly with the emergence of incretin-based therapies. Beyond improving weight and glycemic control, these agents are showing promise in resolving steatohepatitis and slowing fibrosis...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.